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Abstract 
Background: The World Health Organization (WHO) recommends rapid diagnostic tests (RDTs) as a good alternative 
malaria‑diagnosis method in remote parts of sub‑Saharan Africa. The majority of commercial RDTs currently available 
detect the Plasmodium falciparum protein histidine‑rich protein 2 (PfHRP2). There have also been recent reports of 
pfhrp2 gene deletions being found in parasites collected from several African countries. The WHO has concluded that 
lacking the pfhrp2 gene must be monitored in Africa. The purpose of the study was to analyse why the samples that 
were positive by PCR were negative by RDTs and, therefore, to determine whether there have been deletions in the 
pfhrp2 and/or pfhrp3 genes.
Methods: Malaria NM‑PCR was carried out on all the samples collected in the field. A group of 128 samples was posi‑
tive by PCR but negative by RDT; these samples were classified as RDT false‑negatives. PCR was carried out for exon2 
of pfhrp2 and pfhrp3 genes to detect the presence or absence of these two genes. Frequencies with 95% confidence 
intervals (CIs) were used for prevalence estimates. Associations were assessed by the Chi square test or Fisher´s exact 
test. The level of significance was set at p ≤ 0.05. Statistical analyses were performed using the software package 
SPSSv.15.0.
Results: After PCR, 81 samples were identified (4.7%, 95% CI 3.8–5.8) which had deletion in both genes, pfhrp2 and 
pfhrp3. Overall, however, 11 samples (0.6%, 95% CI 0.36–1.14) had deletion only in pfhrp2 but not in pfhrp3, and 15 
(0.9%, 95% CI 0.6–1.5) presented with deletion only in pfhrp3 but not in pfhrp2. Considering the pfhrp2 gene sepa‑
rately, within the total of 1724 samples, 92 (5.3%, 95% CI 4.37–6.5) had evidence of deletion.
Conclusion: The present study provides the first evidence of deletion in the pfhrp2 and pfhrp3 genes in P. falcipa-
rum isolates from Equatorial Guinea. However, larger studies across different regions within the country and across 
different seasonal profiles are needed to determine the full extent of pfhrp2 and pfhrp3 deletion. It is strongly recom‑
mended to implement an active surveillance programme in order to detect any increases in pfhrp2 and pfhrp3 dele‑
tion frequencies.
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Background
Equatorial Guinea (EG) in Central West Africa is divided 
into two regions, the Insular Region (Bioko, Annobon) 
and the Continental Region (Rio Muni). Malaria remains 
a major public health problem in the country, and EG is 
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According to official data from EG’s National Malar-
ial Control Programme, the prevalence of falciparum 
malaria in the country (for children between 2 and 
14  years old) was 12.5% in 2018. Malaria prevalence 
on Bioko Island was 10.3 and 46.5% in the Continental 
Region. The 2018 Malaria Report does not report preva-
lence for the different species, however, 2011 data for the 
Continental Region show that 95.2% of malaria infections 
were Plasmodium falciparum and 9.5% Plasmodium 
vivax, with eight cases of mixed infection [2].
The main malaria-control strategy is quick and accu-
rate diagnosis followed by effective treatment [3]. Early 
and accurate diagnoses are essential for both effective 
disease management and for proper malaria surveillance. 
The quality of malaria diagnosis is important in all set-
tings, as misdiagnosis can result in significant morbidity 
and mortality.  Since 2010, the World Health Organiza-
tion (WHO) has recommended that all patients with sus-
pected malaria should have their diagnoses confirmed 
by microscopy or a rapid diagnostic test (RDT) before 
treatment [4]. Microscopy and RDTs are the primary 
choices for malaria diagnosis in the field. Furthermore, in 
remote parts of sub-Saharan Africa, RDTs have become 
the primary tool for the parasitological diagnosis or 
malaria confirmation [5]. In the absence of well-trained 
technicians for microscopic diagnosis of malaria in many 
areas, the WHO recommends RDTs as a good alternative 
malaria-diagnosis method [6, 7].
RDTs are commonly used in malaria case-management 
and elimination programmes especially in remotes areas 
where microscopy facilities are not available [8]. As the 
tests are easy to perform and provide rapid results (15–
20 min), they are exceedingly useful for rapid and malaria 
diagnosis in most malaria-endemic areas [9]. The major-
ity of commercial RDTs currently available detect the P. 
falciparum protein histidine-rich protein 2 (PfHRP2), 
which P. falciparum only expresses in blood during the 
ring stage [10]. However, the failure to detect and treat 
false-negative infection increases the risk that people in 
a given community can contribute to onward infection 
through mosquitoes. False negative: that sample which 
is negative by RDT and positive by another diagnostic 
method, in this case NM-PCR for malaria.
The antibodies on the test strip detect the PfHRP2 
antigen but may cross-react with proteins expressed by 
another member of the HRP family, PfHRP3, as there are 
very similar amino acid sequences [9]. Procurement deci-
sion-makers’ general preference for PfHRP2-based RDTs 
is largely based on the findings of a number of studies 
which report that these tests are both more sensitive 
and heat-stable than the RDTs that detect other malaria 
antigens such as Plasmodium lactate dehydrogenase, 
whether pan-pLDH (all species) or P. falciparum-specific 
(Pf-pLDH) or aldolase-based tests [11]. The major draw-
backs for RDTs are false positives, because PfHRP2 per-
sists in the blood for several days after an infection has 
been cleared [12], and false negatives that can be due to 
pfhrp2/pfhrp3 gene deletions, have been observed for 
HRP2 in African field-isolates [13]. In 2010, Gamboa 
et al. reported the first confirmed identification of P. falci-
parum parasites with pfhrp2/pfhrp3 gene deletions; these 
parasites, which expressed neither PfHRP2 nor PfHRP3, 
were identified in the Peruvian part of the Amazon River 
basin [9]. There have also been recent reports of HRP2 
deletions being found in parasites collected from several 
African countries, including the Democratic Republic of 
the Congo, Ghana, Kenya, and Rwanda, in addition to 
India [5, 14–17]. Importantly, patients with false nega-
tives may not receive treatment at all or may receive it 
later. Due to the increase in reports of RDT false-nega-
tives in African countries, the WHO has concluded that 
malaria parasites lacking the pfhrp2 gene must be rigor-
ously monitored [8].
RDTs were introduced in EG in 2010, although micros-
copy is still considered the ‘gold standard’ for malaria 
diagnosis in the country. In 2017, 60,798 RDTs were dis-
tributed in EG to different hospitals and health centres 
[18].
The objective of the present study was to analyse why 
the samples were positive by nested multiplex-PCR (NM-
PCR) and microscopy was negative using RDTs, and, 
therefore, to determine whether there have been dele-




The survey was carried out in the district of Bata in the 
Litoral Province of the Continental Region of EG, located 
between Cameroon and Gabon (Fig.  1). The region has 
a tropical climate with two dry seasons (December to 
March, June to September) alternating with two rainy 
seasons (March to June, September to December). The 
mean daily maximum temperatures are 29–32 °C and the 
minimum temperatures, 19–22 °C.
Study population
The samples were collected from a cross-sectional sur-
vey conducted in June–August 2013 in Bata as part of a 
project called ‘PREVAMAL’. A total of 1741 individuals 
(1043 in urban settings and 698 in rural) were recruited 
[19, 20]. Figure 1 shows the different locations where the 
samples were collected.
Blood samples were taken from participants’ fingers 
for malaria diagnosis using both RDTs and microscopy. 
The blood was spotted on Whatman 903™ paper (GE 
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Healthcare Bio-Sciences Corp.) for further molecu-
lar studies. The blood on the filter paper was air dried, 
stored in double zip-lock plastic bags with silica gel at 
4 °C, and subsequently transported to the National Cen-
tre for Tropical Medicine, Institute of Health Carlos III, 
Madrid (Spain) for diagnostic confirmation by PCR.
Microscopy
The samples were taken in participants’ homes, and the 
thick and thin slides were also prepared on site. The 
peripheral blood specimen slides were made immediately 
after collection on clean, grease-free microscope slides 
and allowed to air dry. The films were stained with 10% 
Giemsa solution (Appichem, Panreac ITW Companies) 
for 10  min, and examined by WHO-certified micros-
copists from the National Malaria Programme of EG’s 
Ministry of Health and Social Welfare. After air drying, 
each slide was subjected to an oil immersion objective 
lens examination; all fields were examined before declar-
ing a slide negative. For each specimen, the thick films 
were examined first in order to detect malaria parasites; 
the thin films of each specimen were only then exam-
ined for speciation in those instances when parasites had 
already been identified in the thick film. The slides were 
each examined by two microscopists; each specimen was 
examined independently, and the result was recorded as 
positive when both microscopists found both evidence of 
a malaria parasite, and identified the same species. In the 
event of a discrepancy, a third microscopist also assessed 
the slide.
Rapid diagnostic test
The RDT used in  situ was the  NADAL®  Malaria 4 spe-
cies test (Test cassette) (Nal von Minden, Moers, Ger-
many). This test enables differential diagnosis between 
P. falciparum, P. vivax, Plasmodium malariae and Plas-
modium ovale in human whole-blood samples. It detects 
HRP2-specific proteins for P. falciparum, and pLDH-
specific proteins for P. falciparum, P. vivax, P. malariae, 
and P. ovale. The test has a sensitivity of 99.7% for P. fal-
ciparum and 95.5% for non-P. falciparum parasites with 
the microscopic detail of a large droplet, and a specific-
ity of 99.5%. The cut-off level was 1 to 50 parasites/µl of 
blood for HRP2 and 51 to 100 parasites/µl of blood for 
pLDH. To perform the malaria test, 5 µl of whole blood 
is collected with the provided capillary pipette and trans-
ferred to the sample well. Four drops of the assay dilu-
ent are then added to the diluent well, in accordance with 
the manufacturer’s protocol. The results are read after 
15–20  min; only tests containing the control band are 
Fig. 1 Map of the Continental Region of Equatorial Guinea. The Littoral Province where the sampling took place is highlighted Source https ://www.
carte dumon de.net, modified. This map was used in Berzosa et al. [20]
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considered valid. Participants whose RDTs produced 
positive results were immediately offered treatment as set 
out by the EG national guidelines [21].
DNA extraction and molecular analysis
The DNA was extracted from the filter paper samples 
using commercial kits (Speedtools tissue DNA Extrac-
tion Kit, Biotools, Spain). A 5-mm diameter punch was 
used that contained 10 μl of blood.
A. NM-PCR for the diagnosis of malaria: The target 
selected in this NM-PCR is the gene encoding the 
18S small sub-unit ribosome RNA (ssrDNA) and 
includes an internal amplification control to avoid 
false negatives (18S human rRNA) [22–24]. This was 
carried out on all the samples collected in the field, 
including both positives and negatives by micros-
copy and by RDTs irrespective of the result. After the 
NM-PCR tests had been completed, a group of 128 
samples was identified for further study; these sam-
ples were positive using PCR and by microscopy, but 
negative using RDTs. Therefore, these samples were 
classified as RDT false-negatives.
B. Nested PCR for pfdhfr, pfdhps, pfmdr1 and pfcrt 
genes: These genes were studied in the RDT false-
negative samples, in accordance with the Mary-
land University protocols [25]. The nested-PCR 
included the following fragments of each gene: pfdhfr 
(108/164, 51/59), in pfdhps (400 and 500), in pfmdr1 
(86/1246) and pfcrt (76). This nested-PCR was used 
as a control for the quality of the DNA. Thus, if all the 
samples worked in the PCR of these genes, this indi-
cates that the DNA has quality for the PCR. There-
fore, if no exon2 amplification fragment is obtained 
from the pfhrp2 and pfhrp3 genes, it was not due to 
poor DNA quality or other factors, but because there 
was a true deletion in the pfhrp2/3 genes.
C. PCR for exon2 of pfhrp2 and pfhrp3 genes The 128 
samples with intact parasite-DNA confirmed by NM-
PCR and pfdhfr, pfdhps, pfmdr1 and pfcrt nested-
PCR were used for further amplification of the exon 
2 of pfhrp2 and pfhrp3 genes. This was to detect the 
presence or absence of these two genes [5, 6, 26]; this 
test was performed as described previously, with the 
same primers but with some minor changes.
pfhrp2-F1 (5′-CAA AAG GAC TTA ATT TAA ATA 
AGA G-3′)/pfhrp2-R1 (5′-AAT AAA TTT AAT GGC GTA 
GGCA-3′) were designed to anneal to the 5′ and 3′ends 
of exon 2 of pfhrp2. Seminested amplification was per-
formed by use of the primers pfhrp2-F2 (5′-ATT ATT 
ACA CGA AAC TCA AGCAC-3′) and pfhrp2-R1. The 
same procedures and conditions were used to amplify 
the pfhrp3 gene by use of the primers pfhrp3-F1 (5′-AAT 
GCA AAA GGA CTT AAT TC-3′), pfhrp3-R1 (5′-TGG 
TGT AAG TGA TGC GTA GT-3′), and pfhrp3-F2 (5′-AAA 
TAA GAG ATT ATT ACA CGA AAG -3′). These changes 
included the use of Biotools Hotsplit DNA polymer-
ase (5U/µl) (Biotools B&M Labs, S.A. Madrid, Spain), 
and the PCR conditions were, 1st PCR y 2nd PCR: 95C 
for 15 min, followed 30 cycles by 95C for 1 min, 60C for 
1 min, and 72C for 1 min and final extension 72C 10 min, 
for both genes. Plasmodium falciparum 3D7 strain para-
site was used as a positive control for pfhrp2 and Dd2 as a 
negative. This is because 3D7 is known to have all pfhrp2 
and pfhrp3 genes, as well as the relevant flanking genes, 
while Dd2 lacks both pfhrp2 and its flanking genes. All 
the positive amplifications of pfhrp2 and pfhrp3 genes 
(exon2) were sequenced from both directions using for-
ward and reverse primers of exon2. PCR products were 
purified with Ilustra exoprostar 1-step (GE Healthcare 
Life Sciences) in accordance with the manufacturer’s 
instructions and were used in a standard dye terminator 
(Big Dye Terminator v3.1 Cycle Sequencing kit); the DNA 
was then sequenced using an ABI PRISM 3730 XL Ana-
lyser. BLAST (Basic Alignment Search Tool) was used 
for the sequence analysis, and homology with pfhrp2 and 
pfhrp3 of P. falciparum were established using MultAlin 
[27] and Sequence Manipulation Suite [28].
Statistical analysis
Frequencies with 95% confidence intervals (CIs) were 
used for prevalence estimates. Associations were assessed 
by the Chi square test or Fisher´s exact test. The level of 
significance was set at P ≤ 0.05. Statistical analyses were 
performed using the software package SPSSv.15.0.
Results
A total of 1724 blood samples were diagnosed by micros-
copy, NM-PCR and RDT [20]. The Plasmodium spp. 
samples marked as negative by both microscopy and 
RDT were tested by NM-PCR as a quality control of 
the diagnoses. In this group of negative-by-RDT sam-
ples (n = 963), 128 (7.4%) were identified as false nega-
tives by PCR and were diagnosed as: 122 P. falciparum, 
1 P. falciparum/P. vivax, 1 P. malariae, 1 P. vivax and 1 
P. ovale. Figure 2 shows how the 1724 samples were pro-
cessed. The 128 negative by RDT samples could have 
been due to a number of possible causes: deletion in the 
pfhrp2 or pfhrp3 genes, technicians’ misinterpretation, or 
that there is parasitaemia in the sample that is lower than 
the minimum detection threshold for RDTs.
The DNA from the 128 false negatives by RDT was 
amplified correctly by the nested-PCR for the follow-
ing genes of P. falciparum (Fig.  3): pfdhfr (108/164 and 
51/59, product sizes 254  bp and 113  bp, respectively), 
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pfdhps (400 and 500, product sizes 148  bp and 201  bp, 
respectively), pfmdr1 (86 and 1246, product sizes 
203  bp and 295  bp, respectively) and pfcrt (76, prod-
uct size 145  bp). This indicates that the DNA has been 
extracted correctly, that it has no inhibition factors for 
PCR and that it has sufficient concentration to be used 
successfully in the PCR of exon2 of pfhdrp2 and pfhrp3 
genes. All the DNA samples were studied for the dele-
tion of pfhrp2 and pfhrp3 using PCR (PCR for exon2 of 
the pfhrp2 and pfhrp3 genes); the sizes of the expected 
fragments, if amplification did occur, were ± 814  bp 
for pfhrp2 and ± 719 bp for pfhrp3; this determined the 
presence or absence of these genes in the samples. Fig-
ure  4 shows the result of the PCR tests. The decision 
was made to perform the PCR for exon2 of pfhrp2/3 in 
all samples that were negative for RDT and positive for 
NM-PCR, although some samples were diagnosed as 
non-falciparum. In the non-falciparum samples, amplifi-
cation fragment for pfhrp2/3 was not to be obtained. In 
this way it was also tested the specificity of the PCR for 
exon2 pfhrp2/3, as it only amplify these genes of P. falci-
parum. This PCR does not give false positives (amplifi-
cation fragment with other species of Plasmodium), that 
is, the non-falciparum samples acted as negative controls 
for the PCR.
After carrying out the PCR on 128 RDT false-negative 
samples, 5 non-falciparum (1 P. malariae, 3 P. ovale, 1 P. 
vivax) samples were, as expected, negative in the pfhrp2/
pfhrp3-PCR. The mix sample (P. falciparum/P. vivax) was 
negative in the PCR for these two genes, therefore, was 
659 + 128= 787 (45.6%) real positives (763 P. falciparum)























Fig. 2 Sample Processing Flowchart. It is observed that 963 samples out 1724 were negatives by RDT and 761 positives. By NM‑PCR was detected 
inside the negative group 128 positive samples (122 Pf, 1 Pm, 3 Po and 1 Pv/Pf ), therefore, they were false negatives. The frequency of false 
negatives by RDT is 7.4%. In these 128 samples were studied the Pfhrp2 and Pfhrp3 genes. All these data are published in a previous article Berzosa 
et al. [20]





Fig. 3 Results of the Nested PCR for Pfdhfr, Pfdhps, Pfmdr1 and Pfcrt genes: amplification appears in all cases, therefore, it indicates that the DNA 
was well extracted and works correctly in PCR. These PCRs are used as a control, all samples amplified perfectly so when no amplification appears in 
pfhrp2/3 indicates for sure that there is deletion, it is not a problem with the DNA
PCR-pfhrp2-exon2 PCR-pfhrp3-exon2
5 421              21              
a b
3  
Fig. 4 Results of the Nested PCR for Pfhrp2/3; the presence of the amplification fragment indicates the presence of the gene: figure (a), lines 
1/2/3/4/5 (± 814 bp for Pfhrp2) and figure (b) lines 1/2 (± 719 bp for Pfhrp3). When the fragments do not appear indicate that deletion exists; 
fragments are sequenced to confirm that they correspond to the pfhrp2/3 genes
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detected deletion in these genes for P. falciparum. In the 
remaining 122 samples which were P. falciparum, 81 sam-
ples were identified (4.7%, 95% CI 3.8–5.8) out of 1724 
which had deletion in both genes (Table  1); therefore, 
the amplification fragment was absent. Fifteen samples 
(0.87%, 95% CI 0.53–1.43) had no identifiable deletion in 
any of the genes studied. In this last case, the expected 
amplification fragments appeared and were purified and 
sequenced, and after the comparison in BLAST they 
were found to have homology with the exon2 of the two 
genes under study. Overall however, 11 samples (0.6%, 
95% CI 0.36–1.14) had deletion only in pfhrp2 but not 
in pfhrp3, and 15 (0.9%, 95% CI 0.6–1.5) presented with 
deletion only in pfhrp3 but not in pfhrp2. Considering 
the pfhrp2 gene separately (the RDT detects the protein 
pfhrp2), within the total of 1724 samples, 92 (5.3%, 95% 
CI 4.37–6.5) had evidence of deletion. In the mixed infec-
tion (P. falciparum/P. vivax) according to NM-PCR, nei-
ther the pfhrp2 nor the pfhrp3 genes were detected.
If the prevalence of deletion is calculated taking 
account the number of P. falciparum detected by SnM-
PCR (763) the frequencies for each case were: deletion in 
both genes, 10.6% (95% CI 8.62–13); no deletion in any 
gene, 2% (1.97%; 95% CI 1.19–3.22); deletion in pfhrp2 
but not in pfhrp3, 1.4% (95% CI 0.81–2.56); deletion in 
pfhrp3 but not in pfhrp2, 2% (1.9%; 95% CI 1.19–3.22). 
Deletion just in pfhrp2 was 12% (95% CI 9.94–14.56) 
(Table 1).
Discussion
This study provides the first evidence of pfhrp2 and 
pfhrp3 deletions in P. falciparum in EG. The pfhrp2 
deletion prevalence found in the samples was 5.3%; this 
prevalence is low when compared to that of Ghana (30%), 
but is very similar to Mali (5%) [15, 29, 30]. As yet, there 
are no data available for pfhrp2 and pfhrp3 deletion in 
neighbouring Cameroon and Gabon. The WHO guide-
lines consider a pfhrp2 deletion prevalence of 5% as a 
minimum threshold to change RDT types [31], or, and 
if not possible, confirm the result of the RDT by another 
technique, such as microcopy. This study identified 5.3% 
pfhrp2 deletion in the regional sample; moreover, this 
shows that it is now necessary to monitor the deletion 
of this gene across the whole country in order to obtain 
a complete picture of the deletions occurring with these 
genes. It is important to remember that this study was 
carried out in a district of EG’s continental region; it is 
evident that the study needs to be extended to cover the 
country in its entirety.
Deletions in pfhrp3 were also detected in the study, 
although the RDT used in EG and for this study was not 
designed to detect pfhrp3 proteins. In most settings, 
genetic mutations like pfhrp2/pfhrp3 deletion in para-
sites are unlikely to be the main cause of RDT false-neg-
atives unlike in this study, and more studies are required 
to establish the true prevalence of these mutations in EG. 
In fact, there were some samples that were RDT false-
negatives which were found to be positive using NM-
PCR, but without any detectable deletion in the phrp2 
and pfhrp3 genes. Therefore, these results might be due 
to problems with the RDT used itself, or as result of oper-
ator error when carrying out tests and/or interpretation 
RDT results; all of which could result in false-negatives 
[32].
Attributing false-negatives to pfhrp2/pfhrp3 dele-
tion has significant implications for public health policy. 
Once it has been established that the threshold has been 
passed, alternative RDTs will have to be procured and 
case-management decisions will have to be revised, with 
retraining in the use of the new RDTs. Investigation into 
such deletions must be carried out systematically and 
accurately [7]. If pfhrp2 deletions are found to be preva-
lent among symptomatic individuals (the lower 95% CI 
is still above 5%), as is the case, for example, in Eritrea 
and several countries in South America (Brazil, Colom-
bia, Peru), national malaria control programmes will have 
Table 1 Samples in which deletion is detected in Pfhrp2 and Pfhrp3 genes
It is observed that in 81 samples appear deletion in both genes; 15 have no deletion in either of them, 11 have deletion only in Pfhrp2, 15 only in Pfhrp3. Regardless of 
what happens in Pfhrp3 (whether there is or not deletion), there are 92 samples with deletion in Pfhrp2. In the mixed infection case, is detected deletion in both genes
N = 1724 number of total samples, N = 763 total of P. falciparum samples by PCR
D deletion/ND no deletion/NC not considered
Samples No of samples Pfhrp2 Pfhrp3 N = 1724 (%) 95% CI N = 763 (%) 95% CI
P. falciparum (N = 122) 81 D D 4.7 3.8–5.8 10.6 8.62–13
15 ND ND 0.87 0.53–1.43 1.97 1.19–3.22
11 D ND 0.6 0.36–1.14 1.4 0.81–2.56
15 ND D 0.87 0.53–1.43 1.9 1.19–3.22
92 D NC 5.3 4.37–6.5 12 9.94–14.56
Mixed infection (Pf/Pv) (N = 1) 1 D D 0.06 1e‑04–0.33 0.1 2e‑04–0.74
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to switch to RDTs that do not exclusively rely on PfHRP2 
to detect P. falciparum. A 5% threshold was selected by 
WHO because it is somewhere around this point that 
the proportion of cases missed by PfHRP2 RDTs due 
to non-hrp2 expression is likely to be greater than that 
which would be missed by using less-sensitive pLDH-
based RDTs. A recommendation to switch can be fur-
ther informed by mathematical modelling which shows 
whether parasites lacking pfhrp2 genes will spread under 
PfHRP2-only RDT pressure; policy makers may also 
decide to switch because of the complexity of procuring 
multiple RDTs and training staff in their use. In general, 
any change should be applied nationwide, although roll-
out might be prioritized on the basis of PfHRP2-deletion 
prevalence in a given region [33]. Where microscopy is 
available, services should be strengthened to ensure that 
parasitological confirmation continues during the transi-
tion to new RDTs, and in order to investigate new, sus-
pected PfHRP2/PfHRP3-deleted parasite foci.
Excessive use of pfhrp-based RDTs might enhance 
the selection of P. falciparum isolates with pfhrp2 dele-
tion, especially in endemic areas where pfhrp2 deletion 
is present, as the case in EG. Previous reports have also 
shown that pfhrp3 deletion can be an early warning sign 
for pfhrp2 deletion. Thus, it is important to monitor 
the presence of parasites with pfhrp2 deletions to avoid 
RDT false-negatives, as well as pfhrp3 deletions to act as 
an early warning, which offers public health bodies an 
opportunity to step up monitoring efforts and consider 
longer term contingency plans [8, 9].
Conclusion
The RDTs used in this study detected the majority of P. 
falciparum infections as well as those from other species. 
Regarding the deletion of the genes, it is strongly recom-
mended to implement an active surveillance programme 
in order to detect any increases in pfhrp2 and pfhrp3 
deletion frequencies. Although there are false negatives 
due to causes other than deletion of these genes, a sur-
veillance programme is critical due to the level of fre-
quencies of deletion detected in the study. Surveillance 
could be implemented in different regions and different 
seasonal profiles, to determine the full extent of pfhrp2 
and pfhrp3 deletion.
To be able to control malaria, it is essential to have 
good diagnostic tools on the front line. To this end, the 
present study provides the first evidence of deletion in 
the pfhrp2 and pfhrp3 genes in P. falciparum isolates 
from EG. If frequency of deletion increases over time in 
the country, it might be important to think about chang-
ing the type of RDTs used.
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